New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC – Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company,… Read More
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety… Read More
VANCOUVER, BC – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to… Read More
Tzield® is demonstrated to delay by a median of 2 years the onset of Stage 3 type 1 diabetes in patients 8 years of age and older currently with Stage… Read More
Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI At 9 months… Read More
